APPARATUS AND METHOD FOR MEASURING CONCENTRATION OF MOLECULES THROUGH A BARRIER

• US 20100041021A1
• Filed: 08/20/2009
• Published: 02/18/2010
• Est. Priority Date: 08/05/2004
• Status: Abandoned Application

• Current Assignee: Ivan E. Modrovich
• Original Assignee: Ivan E. Modrovich
• Inventors: Modrovich, Ivan E.
• Application Number:
  US12/544,421
• Publication Number:
  US 20100041021A1
• Time in Patent Office: Days
• US Class Current: 435/5
• CPC Class Codes: A61B 5/14532 for measuring glucose, e.g. by tissue impedance measurement
• CPC Class Codes: A61B 5/1486 using enzyme electrodes, e.g. with immobilised oxidase
• CPC Class Codes: A61B 5/411 Detecting or monitoring allergy or intolerance reactions to an allergenic agent or substance

Abstract

An apparatus and method for detecting the presence and measuring the concentrations of molecules through a barrier and/or at a distance utilizes the principle of chemical/electrostatic attraction (hereinafter “affinity”), i.e., the affinity between charged atoms and molecules that cause their chemical interactions and reactions, to infer, based on the behavior of molecules on one side of the barrier, the presence and concentration of corresponding molecules on the other side of the barrier. The invention is useful, by way of example and not limitation, in non-invasively measuring glucose levels of diabetic patients.

Claims

1-34. -34. (canceled)

35. A method for detecting, through a barrier, whether target entities are present in a sample suspected of containing said target entities, comprising the steps of:

providing a probe in which are situated a plurality of measuring agents;

bringing the probe toward the sample and measuring changes in a characteristic of the measuring agents if said target entities are present in the sample, said changes resulting from affinity forces between the target entities and the measuring agents, the affinity forces causing said changes to occur even though said target entities and measuring agents are separated by said barrier; and

inferring that said target entities are present in said sample if said changes are measured, and inferring that said target entities are not present in said sample if said changes are not measured.

36. A method as claimed in claim 35, wherein said target entities are selected from the group consisting of atoms, compounds, and molecules, said atoms, compounds, and molecules capable of exerting strong enough affinity forces on complimentary atoms, compounds, or molecules to produce said measurable changes, one or more of said complimentary atoms, compounds or molecules being selected as the measuring agents.

37. A method as claimed in claim 35, wherein said target entities include a target molecule and said measuring agents include a measuring molecule.

38. A method as claimed in claim 37, further comprising the step of determining, based on said measurement of changes, a concentration of said target molecule.

39. A method as claimed in claim 37, wherein the characteristic is spatial orientation.

40. A method as claimed in claim 39, wherein said measurable changes are measurable changes in said orientation that are detected by measuring a resistivity of a material in which said measuring molecule is suspended.

41. A method as claimed in claim 40, wherein said material, in which said measuring molecule is suspended, is a gel.

42. A method as claimed in claim 39, wherein said target entities include a substrate and said measuring molecule is an enzyme.

45. A method as claimed in claim 39, wherein said target entities include an antigen and said measuring molecule is an antibody.

46. A method as claimed in claim 39, wherein said target entities include an antibody and said measuring molecule is an antigen.

47. A method as claimed in claim 39, wherein said method is arranged to test for allergic reactions.

48. A method as claimed in claim 39, wherein said target entities include a c-reactive protein (CRP) and said measuring molecule is a CRP specific monoclonal antibody.

49. A method as claimed in claim 39, wherein said method is arranged to test for indications of infectious biological entities.

50. A method as claimed in claim 49, wherein said method is arranged to detect antibodies produced in response to microorganisms.

51. A method as claimed in claim 49, wherein said method is arranged to detect a concentration of said biological entities.

52. A method as claimed in claim 49, wherein said method is arranged to detect a concentration of antibodies produced in response to microorganisms.

53. A method as claimed in claim 49, wherein said biological entities are viruses or bacteria.

54. A method as claimed in claim 39, wherein said target entities include immunogobulins.

55. A method as claimed in claim 39, wherein said immunogobulins are selected from the group consisting of IgG, IgM, and IgA.

56. A method as claimed in claim 39, wherein said target entities include lipoproteins.

43. (canceled)

44. (canceled)